摘要
糖尿病和阿尔茨海默病(AD)的发病率都在增加,并正在成为世界范围内的社会和经济威胁。最近的研究表明,这两种疾病都有一些病理生理特征,特别是2型糖尿病(T2DM)是阿尔茨海默病的危险因素。本研究旨在探讨糖尿病与AD的关系,探讨某些药物对糖尿病及AD的疗效,并在不同临床研究中比较糖尿病患阿尔茨海默病的相对风险。在2000-2015年期间,在“科学网”、“Elsevier Science Direct”、“PubMed”和“Scopus”等几个公认的数据库中使用文献检索方法,检索下列关键词:“阿尔茨海默氏症和疾病、糖尿病和糖尿病”。所确定的研究根据其重点分为两个基本组:选定药物对AD和糖尿病患者的疗效,以及糖尿病与AD之间的联系;AS糖尿病被视为AD的一个危险因素。本研究结果证实糖尿病与AD有密切而直接的联系,提示有必要对代谢综合征、胰岛素抵抗和T2DM进行早期诊断。事实上,经过审查的临床试验证明,患AD的风险增加了。然而,这一风险的价值相对较低。结果还表明,药理学治疗(如抗糖尿病药物和胰岛素剂量)和非药理学治疗(例如,密集从事体育活动)都可以起到积极的作用。本研究结果证实糖尿病和AD并不是独立的疾病,因为它们有一些共同的病理生理机制。此外,还需要更多的临床随机对照试验来探索治疗T2DM和AD的药理学和非药理学方法的有效性。
关键词: 阿尔茨海默病,慢性疾病,糖尿病,痴呆,危险因素,系统综述。
Current Alzheimer Research
Title:Global View on Alzheimer’s Disease and Diabetes Mellitus: Threats, Risks and Treatment Alzheimer’s Disease and Diabetes Mellitus
Volume: 15 Issue: 14
关键词: 阿尔茨海默病,慢性疾病,糖尿病,痴呆,危险因素,系统综述。
摘要: The incidence of both diabetes and Alzheimer’s disease (AD) is increasing and is becoming a social and economic threat worldwide. Recent research studies indicate that both diseases share some pathophysiological features and that specifically, Type 2 Diabetes Mellitus (T2DM) is a risk factor of Alzheimer’s disease. The aim of this study is to explore the relationship between diabetes mellitus and AD, explore the efficacy of selected drugs on patients with diabetes and AD, and compare the relative risk of diabetes for Alzheimer’s disease within different clinical studies. The method of literature search in several acknowledged databases such as Web of Science, Elsevier Science Direct, PubMed and Scopus in the period from 2000 to 2015 for the following keywords: “Alzheimer’s AND disease AND diabetes AND mellitus” was used. The identified studies were divided into two basic groups, based on their focus: efficacy of the selected drugs on patients suffering from AD and diabetes, and a link between diabetes and AD; as diabetes is seen as a risk factor of AD. The findings of this study confirm that there is a close and direct link between diabetes and AD, which indicates that there is a need for early diagnosis of metabolic syndrome, insulin resistance, and T2DM. In fact, the reviewed clinical trials have proved an increase in the risk of AD. However, the values of this risk are relatively low. The results also illustrate that both pharmacological (e.g., the antidiabetic drugs together with insulin dosing) and nonpharmacological (e.g., being intensively engaged in physical activities) treatments can have a positive effect. The results of this study confirm that diabetes and AD are not independent disorders since they share some common pathophysiological mechanisms. In addition, more clinical randomized control trials are needed to explore the efficacy of both pharmacological and non-pharmacological approaches to the treatment of T2DM and AD.
Export Options
About this article
Cite this article as:
Global View on Alzheimer’s Disease and Diabetes Mellitus: Threats, Risks and Treatment Alzheimer’s Disease and Diabetes Mellitus, Current Alzheimer Research 2018; 15 (14) . https://dx.doi.org/10.2174/1567205015666180925110222
DOI https://dx.doi.org/10.2174/1567205015666180925110222 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Approaches to the Diagnosis of Classical form of Congenital Adrenal Hyperplasia
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Advances in Biomarker Research for Pancreatic Cancer
Current Pharmaceutical Design Oxidative stress and Parkinson’s disease: New hopes in treatment with herbal antioxidants
Current Pharmaceutical Design Fc Engineering to Improve the Function of Therapeutic Antibodies
Current Pharmaceutical Biotechnology Why Does Obesity Increase the Risk for Cardiovascular Disease?
Current Pharmaceutical Design The Glomerular Podocyte as a Target of Growth Hormone Action: Implications for the Pathogenesis of Diabetic Nephropathy
Current Diabetes Reviews Antioxidants and its Properties as Affected by Extrusion Process: A Review
Recent Patents on Food, Nutrition & Agriculture A Timely Review of State-of-the-Art Chronopharmaceuticals Synchronized with Biological Rhythms
Current Drug Delivery The Role of 5-AMP-Activated Protein Kinase (AMPK) in Diabetic Nephropathy: A New Direction?
Current Enzyme Inhibition Safety of Canagliflozin in Patients with Type 2 Diabetes
Current Drug Safety Pharmacological Potential of Exercise and RAS Vasoactive Peptides for Prevention of Diseases
Current Protein & Peptide Science Self-Assembly of DNA and Cell-Adhesive Proteins onto pH-Sensitive Inorganic Crystals for Precise and Efficient Transgene Delivery
Current Pharmaceutical Design Assessing Drug Transport Across the Human Placental Barrier: From In Vivo and In Vitro Measurements to the Ex Vivo Perfusion Method and In silico Techniques
Current Pharmaceutical Biotechnology Predementia and Dementia Syndromes: Possible Role of Lipoprotein Metabolism
Vascular Disease Prevention (Discontinued) Soluble CD40L and its Role in Essential Hypertension: Diagnostic and Therapeutic Implications
Cardiovascular & Hematological Disorders-Drug Targets Recent Developments in the Treatment of Alcoholic Chronic Pancreatitis
Current Drug Abuse Reviews The Effectiveness of Interventions to Address Health Inequalities During Pregnancy: A Review of Relevant Literature
Current Women`s Health Reviews Natural AMPK Activators: An Alternative Approach for the Treatment and Management of Metabolic Syndrome
Current Medicinal Chemistry Is Exenatide Improving the Treatment of Type 2 Diabetes? Analysis of the Individual Clinical Trials with Exenatide
Reviews on Recent Clinical Trials Delivery of Peptides Via the Oral Route: Diabetes Treatment by Peptide-Loaded Nanoparticles
Current Pharmaceutical Design